Objective. This study was designed to examine the frequency of natural killer T (NKT) cells and the response to a-galactosylceramide (a-GalCer) in SLE patients and to investigate the clinical relevance of NKT cell levels.
Introduction
NKT cells are a distinct subset of T lymphocytes that are characterized by the restricted expression of TCR (Va24-Ja18/Vb11 in human), which recognizes glycolipid antigens, such as a-galactosylceramide (a-GalCer), presented by the MHC Class I-like molecule CD1d [13] . The most remarkable property of NKT cells is their ability to rapidly produce large amounts of cytokines, such as IFN-g and IL-4, in response to TCR engagement [4] . In turn, the activation of NKT cells leads to the activation of a variety of innate and adaptive immune cells [5] . Indeed, NKT cells have been shown to play crucial roles in a broad range of diseases, including infectious diseases, autoimmunity and cancer [6] .
NKT cell deficiencies have been found in spontaneous and chemically induced models of murine lupus [712] . Furthermore, NKT cell numbers have been reported to be reduced in peripheral blood in several human autoimmune diseases, including RA, SSc, Type 1 diabetes [1315] and SLE [1619] . However, NKT cell numbers were found to be evaluated only in small patient populations [17, 19] , and in other studies, markers non-specific for NKT cells were used [16, 18] . Moreover, the clinical relevance of NKT cells in SLE remains to be clarified.
The marine sponge-derived glycolipid, a-GalCer, has been widely used to study NKT cells both in vitro and in vivo, and it is a promising candidate for NKT cell-mediated therapy [5] . However, it has been reported that the injection of a-GalCer into mice results in the hypo-or unresponsiveness of NKT cells to re-stimulation with a-GalCer [20] . Furthermore, Kojo et al. [17] found a-GalCer non-responders among patients with autoimmune diseases. However, the mechanism involved in poor response to a-GalCer remains unclear.
The first aim of the present study was to examine NKT cell levels in peripheral blood of SLE patients and their proliferative responses to a-GalCer. The second aim was to investigate potential relationships between NKT cell levels and SLE-related clinical parameters. Our final aim was to determine the mechanism involved in poor response to a-GalCer in SLE patients.
Materials and methods

Patients
The study cohort included 128 patients diagnosed as having SLE [88% female, mean age 33 (11) years, mean disease duration 6 (4.7) years] according to the ACR criteria [21] and 92 age-and sex-matched healthy controls (HCs) [80% female, mean 32 (9) 
Co-culture of PBMCs with a-GalCer
Freshly isolated PBMCs were suspended in complete media (RPMI 1640, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin) supplemented with 10% fetal bovine serum (FBS; Gibco BRL, Grand Island, NY, USA). Suspended cells were seeded in a 24-well plate at 1 Â 10 6 cells/well, and then cultured for 7 days at 37 C in a humidified incubator containing 5% CO 2 in the presence of 100 U/ml IL-2 (BD PharMingen, San Jose, CA, USA) and 100 ng/ml a-GalCer (Alexis Biochemicals, Lausen, Switzerland) or 0.1% DMSO (used as a control). To determine proliferative responses of ionomycin-treated PBMCs to a-GalCer, freshly isolated PBMCs from HCs were left untreated or incubated with ionomycin (1 mM; Sigma, Steinhein, Germany) for 24 h, and then cultured for 7 days under the conditions described above. Cells were harvested and stained with FITC-conjugated anti-CD3 and PE-conjugated 6B11 mAbs. Percentages of CD3 /well) were incubated in 500 ml of complete medium supplemented with 10% FBS and a-GalCer (200 ng/ml). After 2 h, 500 ml of medium containing brefeldin A (GolgiPLUG; BD Biosciences, San Diego, CA, USA) were added, and the final concentrations of a-GalCer and brefeldin A were 100 ng/ml and 10 mg/ml, respectively. After an additional incubation time of 6 h, cells were stained with FITC-conjugated anti-Vb11 and PE-conjugated anti-Va24 mAbs at 4 C for 20 min. Cells were then fixed in 4% paraformaldehyde for 15 min at room temperature, and were permeabilized with the Perm/Wash solution (BD Biosciences, San Diego, CA, USA) for 10 min. Cells were stained with APC-conjugated anti-IFN-g mAb for 30 min at 4 C and analysed by flow cytometry.
Co-culture of antigen presenting cells and T cells with a-GalCer
CD14
+ monocytes and CD19 + B cells were purified from PBMCs using magnetic-activated cell sorter (MACS), and used as a source of antigen presenting cells (APCs). CD3 + T cells were also isolated from the remaining PBMCs by MACS. APCs (1 Â 10 5 cells/well) and T cells (9 Â 10 5 cells/well) were seeded in a 24-well plate, and then cultured for 7 days in the presence of 100 U/ml IL-2 and 100 ng/ml a-GalCer or 0.1% dimethyl sulfoxide (DMSO) (control). Co-cultures were subdivided into four subgroups according to the donor origins of APCs and T cells: APCs and T cells from the same HCs; APCs from HCs and T cells from SLE patients; APCs from SLE patients and T cells from HCs; and APCs and T cells from the same SLE patients.
RT-PCR
RT-PCR was performed as described previously [27] . The sequences of the primers used in this study were as follows: b-actin, 
Multiple cytokine assay
This assay was performed to measure human IL-2, IL-4, IL-5, IL-10, IL-12 p70, IL-13, GM-CSF, IFN-g and TNF-a levels. Culture supernatants were harvested, and then the cytokine levels were measured by multiplexed bead-based cytokine assay using Bio-Plex Pro Human Cytokine Th1/Th2 Panel Kits (Bio-Rad Laboratories, Hercules, CA, USA) on the Luminex 100 system (Luminex, Austin, TX, USA).
Statistical analysis
As the distributions were skewed, the percentages and absolute numbers of NKT cells were log-transformed for purpose of analysis and were compared using Student's t-test. Proliferation indices, cytokine levels and expression levels of CD1d were compared in HCs and SLE patients using Student's t-test or MannWhitney U-test. Correlation between the percentage of NKT cells on Day 0 and the percentage of NKT cells on Day 7 was determined by Pearson's correlation coefficient. After categorical variables were converted to a series of dummy variables, multiple linear regression analysis was used to test for associations between NKT numbers and clinical variables. P < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 14.0 software (SPSS, Chicago, IL, USA).
Results
Reduced numbers of circulating NKT cells in SLE patients
The percentages and absolute numbers of NKT cells in the peripheral blood samples of 128 SLE patients and 92 age-and sex-matched HCs were determined by flow cytometry. Percentages of CD3 + 6B11 + NKT cells were significantly lower in patients than in HCs (median 0.04% vs 0.09%, P < 0.001) (Fig. 1A and C) . Absolute NKT cell numbers were calculated by multiplying NKT cell percentages by total lymphocyte numbers (per microlitre) in peripheral blood. SLE patients had significantly lower absolute numbers of CD3 + 6B11 + NKT cells than HCs (median 0.2 cells/ml vs 1.2 cells/ml, P < 0.001) (Fig. 1B) . Based on the expression of CD4 and CD8, CD3 + 6B11 + NKT cells were subdivided into CD4 + , CD8 + and double-negative NKT cell subsets. However, no significant differences were found between the percentages of these cell subsets in HCs and patients (data not shown).
Correlation between SLEDAI and NKT cell reduction in SLE patients
To evaluate the clinical relevance of NKT cell levels in SLE patients, we investigated relationships between absolute NKT cell numbers in peripheral blood and SLE-related clinical parameters by regression analysis (Table 2) . Univariate linear regression analysis showed that log-transformed absolute NKT cell numbers were significantly correlated with serositis, pericardial effusion, lupus nephritis, CH50, IgG, SLEDAI, Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI), daily steroid dose and immunosuppressive drug (P = 0.041, P = 0.048, P = 0.023, P = 0.041, P = 0.040, P < 0.001, P = 0.026, P = 0.004 and P = 0.031, respectively). After multivariate analysis, only SLEDAI and immunosuppressive drug were found to be significantly correlated with log-transformed absolute NKT cell numbers (P < 0.001 and P = 0.036, respectively) ( Table 2 ).
Impaired proliferative response of PBMCs to a-GalCer in SLE patients
To examine the proliferative effect of a-GalCer on NKT cells, PBMCs from 30 SLE patients and 30 age-and sex-matched HCs were co-cultured with a-GalCer for 7 days in the presence of 100 U/ml IL-2. The magnitude of responses to a-GalCer was highly variable among all study subjects. Subjects were divided into good responders (with a proliferation index of >20) and poor responders (with proliferation index of <20). In HCs, the percentages of good and poor responders were 66.6% (n = 20) and 33.3% (n = 10), respectively. In contrast, the percentages www.rheumatology.oxfordjournals.org
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NKT cells in SLE of good and poor responders in patients were 13.3% (n = 4) and 87% (n = 26), respectively. Overall, proliferation indices were significantly lower in patients than in HCs (median 7.5 vs 28.7, P < 0.001) ( Fig. 2A and B) . In addition, we analysed the relationship between initial NKT cell percentage and expanded NKT cell percentage. In HCs, the initial NKT cell percentage on Day 0 was found to be significantly correlated with expanded NKT cell percentage on Day 7 (P < 0.001). However, this was not found in patients, or rather the increased apoptosis of NKT cells was observed on Day 7 ( Fig. 2C and supplementary figure 1 , available as supplementary data at Rheumatology Online). These findings suggest that response to a-GalCer in patients is unrelated to the initial NKT cell level.
Reduced cytokine expression and secretion from a-GalCer-stimulated PBMCs in SLE patients
To examine cytokine expression in NKT cells, we examined mRNA expression levels of IFN-g and IL-4 in a-GalCer-stimulated PBMCs (Fig. 3A) . In a HC subject, IFN-g and to a lesser extent IL-4 were expressed from within 4 h after stimulation with a-GalCer and both were strongly expressed at 24 h. In contrast, the mRNAs of IFN-g and IL-4 were weakly or not detected in SLE patients at these times. We next measured the secretion levels of several cytokines produced by a-GalCer-stimulated PBMCs from 30 SLE patients and 30 HCs (Fig. 3B ). Supernatants were harvested 7 days after stimulation with a-GalCer and tested for cytokines by multiplexed bead-based cytokine assay using Luminex kits. IL-5, IL-13, GM-CSF, IFN-g and TNF-a levels were found to be significantly lower in patients than in HCs. To determine whether reduced cytokine secretion in response to a-GalCer is specific for NKT cells, IFN-g production was assessed at the single-cell level by intracellular cytokine flow cytometry (Fig. 3C) . Percentage IFN-g + NKT cells
was reduced in SLE patients as compared with HCs. These results suggest that poor response to a-GalCer contributes to the impaired expression and production of cytokines observed in SLE patients. 
Expression levels of CD1d in SLE patients
CD1d is a non-polymorphic MHC Class I-like protein, and is known to be required for the presentation of glycolipid antigens (e.g. a-GalCer) to NKT cells [28, 29] . To determine whether CD1d levels differ between SLE patients and HCs, the percentage of CD1d + cells and mean fluorescence intensity (MFI) of CD1d were determined by flow cytometry in the peripheral blood of 15 SLE patients and 15 age-and sex-matched HCs (Fig. 4A) (Fig. 4A ).
NKT cell dysfunction in SLE patients
We investigated whether the poor response of the PBMCs of patients to a-GalCer was caused by the abnormal presentation of glycolipid on CD1d + cells or NKT cell dysfunction. As we expected, CD14 + monocytes from a HC subject could expand CD3 + 6B11 + NKT cells www.rheumatology.oxfordjournals.org from a HC subject in the presence of a-GalCer (100 ng/ ml) and IL-2 (100 U/ml) (with a proliferation index of 45.5) (Fig. 4B) . In contrast, NKT cells from a SLE patient failed to proliferate in the presence of monocytes from a HC subject (with a proliferation index of 2.8).
Interestingly, monocytes from a SLE patient could expand NKT cells from a HC subject (with a proliferation index of 41.3). However, CD19 + B cells could not efficiently expand CD3 + 6B11 + NKT cells, regardless of the donor (Fig. 4B) . Taken together, these results suggest that poor response to a-GalCer is due to NKT cell dysfunction rather than abnormal presentation of glycolipids on CD1d + cells.
Discussion
In the present study, we found that the percentages and absolute numbers of NKT cells were lower in SLE patients than in HCs. It has previously been reported that NKT cell numbers are reduced in autoimmune diseases [17, 19] . However, in previous studies, only NKT cell numbers were measured in the peripheral blood of SLE patients. Because SLE patients are usually in lymphopenic state (Table 1) , absolute cell numbers are affected by total lymphocyte numbers. Thus, we analysed NKT cell percentages to determine whether NKT cell proportions are lower in the peripheral blood of SLE patients, and we confirmed that NKT cell percentages as well as absolute numbers are lower in patients than in HCs.
Our data indicate that reductions in absolute NKT cell numbers are correlated with SLEDAI, which suggests that NKT cells participate in disease activity control. These findings have also been demonstrated in murine lupus models, in which disease exacerbation was found to be associated with NKT cell depletion [7, 10, 11] . NKT cell numbers were also found to be affected by /well) were cultured for 7 days in the presence of IL-2 (100 IU/ml) and a-GalCer (100 ng/ml), and cytokine secretion were determined by multiplexed bead-based cytokine assay using Luminex kits. Each filled circle represents one donor. The horizontal line indicates the median. ***P < 0.001. (C) Impaired IFN-g production in NKT cells of SLE patients. Freshly isolated PBMCs from five age-and sex-matched HCs and five SLE patients were cultured for 7 days in the presence of IL-2 (100 U/ml) and a-GalCer (100 ng/ml). IFN-g expression in the Va24 + Vb11 + NKT cell population was determined by intracellular flow cytometry as described in 'Materials and methods'
section. Data are shown as the mean (S.E.M.) (left panel). A representative experiment is shown (right panel).
immunosuppressive drugs. To exclude the direct effect of medication on NKT cell numbers, we compared NKT cell percentages and numbers among HCs, naïve SLE patients (i.e. SLE patients without drug exposure) and patients on medication. The NKT cell percentages and numbers of naïve SLE patients were consistently lower than those of HCs (see supplementary figure 2 , available as supplementary data at Rheumatology Online). These data suggest that NKT cell level is affected by disease itself as well as medications.
NKT cells are universally responsive to a-GalCer. However, the extent to which human NKT cells expand in vitro in response to a-GalCer is known to vary considerably between individuals and with age [30, 31] . Two response patterns of NKT cell expansion, that is, good and poor response, were observed among our study subjects, and these have also been observed in other studies [17, 30, 32] . Interestingly, the majority of SLE patients (up to 87%) were poor responders, whereas only 33% of HCs fell into this category. In addition, neither   FIG. 4 The mechanism involved in poor response to a-GalCer in SLE patients. [17, 32, 33] . Taken together, these findings suggest that the in vitro expansion of NKT cells in the presence of a-GalCer is highly donor and underlying disease dependent. The response of NKT cells to a-GalCer stimulation is characterized by the rapid production of various cytokines, such as IFN-g, TNF-a, IL-2, IL-4, IL-10, IL-13 and TGF-b [5, 34] . In the present study, IFN-g and IL-4 were strongly expressed within 24 h of a-GalCer stimulation in HCs, whereas these cytokines were weakly or not expressed in patients. We also found that the production of multiple cytokines, including IFN-g, TNF-a, IL-5, IL-13 and GM-CSF, were markedly reduced in the SLE patients after 7 days of in vitro stimulation with a-GalCer, which suggests that reduced cytokine production may be due to diminished NKT cell growth. Collectively, our data indicate that a-GalCer is relatively ineffective at inducing cytokine production by NKT cells and for expanding NKT cells in SLE patients.
CD1d presents glycolipid antigens (e.g. a-GalCer) on APCs to NKT cells. Thus, it is possible that alterations of CD1d expression influence NKT cell response to a-GalCer. Indeed, blocking experiments using mAb against CD1d or genetic depletion of CD1d have shown that these actions inhibit the proliferative response of NKT cells to a-GalCer [12, 29] . Interestingly, in the present study, we found that the CD1d levels on monocytes were comparable in SLE patients and HCs, whereas CD1d levels on B cells were markedly reduced in patients. Thus, we hypothesized that the poor response to a-GalCer in patients might be due to altered CD1d expression on B cells. However, our co-culture experiment showed that the in vitro expansion of NKT cells in response to a-GalCer was efficiently driven by peripheral blood monocytes, and not by B cells. This failure of B cells to drive NKT cell expansion is probably due to poor presentation of a-GalCer to NKT cells or to the absence of activation signals from CD80/86 co-stimulatory molecules [35, 36] . These findings confirm that NKT cell expansion is dependent on CD1d-expressing monocytes [36, 37] , and suggest that monocytes in peripheral blood, but not B cells, are effective APCs for NKT cells.
One possible explanation for the poor response of NKT cells to a-GalCer is aberrant ligand presentation on CD1d-expressing cells (e.g. monocytes). To investigate this possibility, we performed cross co-culture experiments between monocytes and T cells from different donors. Our findings suggest that monocytes from SLE patients are functional and the poor response to a-GalCer is probably due to a defect in NKT cells. Thus, further study is needed to identify the molecular mechanism for the NKT cell defect in SLE patients.
Rheumatology key messages
. NKT cells in SLE patients are deficient in terms of absolute number and function. . NKT cell deficiency reflects disease activity.
